aeolus pharmaceuticals inc (AOLS) Key Developments
Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome
Jun 26 15
Aeolus Pharmaceuticals Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) exercised $3 million in additional contract options under its advanced research and development contract for AEOL 10150. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health
threats. Aeolus is developing its lead compound, AEOL 10150, as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a contract with BARDA worth up to $118 million. The contract is designed to produce the data necessary for an approval under the FDA "Animal Rule" and for a pre-Emergency Use Authorization (EUA) filing. An approval or pre-EUA would allow the federal government to buy AEOL 10150 for the Strategic National Stockpile under the Pandemic All-Hazards Preparedness Reauthorization Act (PAHPRA). PAHPRA is designed to accelerate the research, development, purchase and availability of effective medical countermeasures for the Strategic National Stockpile.
Aeolus Pharmaceuticals Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015
May 15 15
Aeolus Pharmaceuticals Inc. reported consolidated unaudited earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported contract revenue of $1,189,000 compared with $1,438,000 for the same period last year. Loss from operations was $712,000 compared with $437,000 for the same period last year. Net loss was $712,000 or $0.01 diluted per share compared with $437,000 for the same period last year.
For the six months, the company reported contract revenue of $2,114,000 compared with $2,231,000 for the same period last year. Loss from operations was $1,410,000 compared with $1,132,000 for the same period last year. Net loss was $1,410,000 or $0.01 diluted per share compared with $1,132,000 or $0.01 diluted per share for the same period last year. Net cash used in operating activities was $1,269,000 compared with $349,000 for the same period last year.
Aeolus Pharmaceuticals Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 11:30 AM
May 7 15
Aeolus Pharmaceuticals Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: David C. Cavalier, Chairman of The Board, Chief Financial Officer and Secretary.
Aeolus Pharmaceuticals Inc. Receives Orphan Drug Designation from US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Mar 17 15
Aeolus Pharmaceuticals Inc. announced that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration granting Orphan Drug Designation for AEOL 10150 'for treatment of idiopathic pulmonary fibrosis'. Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits. The company is also developing AEOL 10150 as a treatment for cancer patients receiving radiation therapy and for the pulmonary and delayed effects of acute radiation exposure under a five-year contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014
Feb 13 15
Aeolus Pharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended December 31, 2014. For the quarter, the company reported a net loss of approximately $698,000 or $0.01 per share compared to $695,000 or $0.01 per share, for the three months ended December 31, 2013. Revenue was approximately $925,000 versus revenue of $793,000 for the three months ended December 31, 2013. Loss from operations was $698,000 against $695,000 a year ago. Net cash used in operating activities was $1,070,000 against $335,000 a year ago.